Consensus Omeros Corporation

Stocks

OMER

US6821431029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-10 EDT			5-day change	1st Jan Change
10.28 ^USD	+0.10%		+10.78%	-40.15%

06-26	Omeros Corporation Provides Update On European Marketing Authorization Application For Narsoplimab In TA-TMA	CI
06-26	Omeros to Seek EMA Review After Negative Opinion on Narsoplimab Marketing Application	MT

Evolution of the Average Target: Omeros Corporation

Evolution of the Target Price: Omeros Corporation

Changes in Analyst Recommendations: Omeros Corporation

9c037f88511f33d157.sbW0abehpiv7TuMWNyu4K8sN5wEab3C3tn4WvMO38y8.19zyLsKY40fDJNF_fByAYaNfpVVWJBPhwiFV_bvNvlbf_f4k4MjVbb47lA~88e7de0d7f7c70dd34a29e6df7270507

Analysts' recommendations: Omeros Corporation

25-10-15	Omeros Shares Surge Pre-Bell After Asset Purchase, License Deal With Novo Nordisk	MT
25-06-10	HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target	MT
23-03-15	UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating	MT
22-12-08	UBS Downgrades Omeros to Neutral From Buy, Adjusts Price Target to $2 From $12	MT
22-11-09	BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target is $3	MT
22-06-08	BofA Securities Downgrades Omeros to Neutral From Buy, Sets $4 Price Target	MT
22-01-18	Cantor Fitzgerald Adjusts Omeros' Price Target to $20 From $34, Reiterates Overweight Rating	MT
21-10-19	OMEROS : HC Wainwright Adjusts Price Target on Omeros to $12 From $19, Maintains Buy Rating	MT
21-10-15	OMEROS : UBS Adjusts Price Target on Omeros to $13 From $25 on Drug Filing Deficiencies, Maintains Buy Rating	MT
21-10-11	OMEROS : Wedbush Suspended Coverage on Omeros	MT
21-10-08	OMEROS : JPMorgan Downgrades Omeros to Underweight from Neutral	MT
21-10-06	OMEROS : HC Wainwright Adjusts Omeros' Price Target to $19 from $32, Keeps Buy Rating	MT
21-10-04	OMEROS : Maxim Downgrades Omeros to Hold from Buy	MT
21-10-01	OMEROS : Wedbush Downgrades Omeros to Underperform From Neutral, Lowers PT to $5 From $18 After FDA Delays PDUFA For Narsoplimab	MT
21-10-01	OMEROS : Maxim Group Downgrades Omeros to Hold From Buy	MT
21-09-27	OMEROS : JPMorgan Starts Omeros at Neutral With $15 Price Target	MT
21-06-18	OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target	MT
21-04-26	OMEROS : HC Wainwright Adjusts Omeros' Price Target to $32 From $34, Keeps Buy Rating	MT
21-02-01	OMEROS : UBS Starts Omeros at Buy With $25 Price Target	MT
21-01-20	OMEROS : HC Wainwright Adjusts Omeros' Price Target to $34 from $31, Keeps Buy Rating	MT
21-01-20	OMEROS : Wedbush Adjusts Omeros' Price Target to $18 From $13, Maintains Neutral Rating	MT
20-12-04	OMEROS : Maxim Adjusts Omeros' Price Target to $25 from $20, Keeps Buy Rating	MT
20-11-17	OMEROS : Wedbush Adjusts Omeros' Price Target to $13 From $12, Maintains Neutral Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' Target price divergence	Objective/dr gap
OMEROS CORPORATION	-	+221.32%
ARGENX SE		+11.28%
WUXI APPTEC CO., LTD.		+21.82%
INSMED INCORPORATED		+66.62%
BIONTECH SE		+31.29%
WUXI BIOLOGICS (CAYMAN) INC.		+26.28%
GENMAB A/S		+20.9%
PHARMAESSENTIA CORPORATION		-17.71%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.		+15.29%
EXELIXIS, INC.		-11.78%
Average		+38.53%
Weighted average by Cap.		+20.85%